Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0382 versus placebo added to dapagliflozin and metformin in overweight or obese adults with type 2 diabetes mellitus
2017-002817-78Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MEDI0382 + dapagliflozin + metformin with Placebo + dapagliflozin + metformin (2 arms). Primary endpoint: Change in glucose AUC0-4h during MMTT. Started Oct 2017; status: completed.
02
Drugs
cotadutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-002817-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002817-78.